Qiagen Delivers the Human Druggable Genome siRNA Set
News Sep 30, 2005
Qiagen has announced delivery of its Human Druggable Genome siRNA Set V2.0 to the Scripps Research Institute in Florida.
This second generation siRNA set from Qiagen is designed to enable gene silencing studies of 6992 potential human druggable targets.
siRNAs are designed using the innovative HiPerformance siRNA Design Algorithm, ensuring maximum silencing and minimum risk of nonspecific effects.
“We selected the siRNA set from Qiagen based on our criteria for siRNA design specificity, expertise in high-throughput siRNA synthesis, and dedicated support.” Dr. John Hogenesch, Director of Genome Technology said.
“Biology in the post-genomic era is marked by the desire to study cells, cellular processes, and disease at a genome-wide level.”
“The Genome Technology group at Scripps Florida aims to leverage these high-throughput tools and technologies toward a systematic description of genes encoded by the human genome, and a more comprehensive understanding of the genetic basis for human disease.”
Scripps Florida researchers will use the siRNAs in combination with an assortment of high-throughput phenotypic screening technologies to interrogate mammalian gene function in cell based assays.
“We are delighted that the Scripps Research Institute selected our Human Druggable Genome siRNA Set,” commented Dr. Jie Kang, VP R&D at Qiagen.
“Scripps joins a long list of other pharmaceutical and academic research centers in applying high-throughput RNAi applications with our products and dedicated support.”
“We look forward to more exciting discoveries and publications in this regard.”
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.